SAL001 (teriparatide biosimilar) / Shenzhen Salubris - LARVOL DELTA

Efficacy of once-weekly teriparatide versus alendronate in Chinese postmenopausal osteoporosis: a randomised, open-label, active-controlled, 48-week, multicentre phase III study. (PubMed, J Orthop Translat) - "This study demonstrates that once-weekly teriparatide significantly improves bone mineral density and reduces fracture risk in postmenopausal osteoporosis patients. As a patient-friendly alternative to daily injections, it may enhance adherence and inform clinical guidelines, representing a promising strategy for patients and healthcare systems."

Journal • P3 data • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Biosimilarity Assessment of the Biosimilar Teriparatide Candidate and the Reference Drug in Healthy Subjects. (PubMed, Clin Pharmacol Drug Dev) - "Other PK parameters, serum calcium concentration, and safety profiles had no significant differences between the 2 formulations. SAL001 demonstrated PK similarity to the reference drug, and the serum calcium concentration and safety profiles of SAL001 were also considered comparable to the reference drug."

Journal • Osteoporosis • Rheumatology